Buy Neurocrine (NBIX) Ahead of Elagolix Phase 3 Data, MKM Partners Says

February 7, 2014 1:37 PM

MKM Partners analyst John LeCroy is more positive on Neurocrine Bio. (NASDAQ: NBIX) as Elagolix Phase 3 data is fast ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found